06/23/2026
We are excited to share that a new Phase 2 clinical trial evaluating Surlorian (ARM210, S48168) for adults with autosomal dominant RYR1-related myopathy (RYR1-RM) is now enrolling participants across multiple sites in Europe. ๐
The study, sponsored by RyCarma Therapeutics, will evaluate whether this investigational treatment may help improve muscle weakness while assessing safety and tolerability.
Adults ages 18 - 65 with a confirmed genetic diagnosis of autosomal dominant RYR1-RM who are able to walk 10 meters with or without a cane may be eligible. To learn more visit: https://clinicaltrials.gov/study/NCT07560020?term=NCT07560020&viewType=Card&rank=1